This study provides evidence that Shh pathway activation, as assessed by high levels of plasma Shh at diagnosis, is associated with resistance to EGFR TKIs in EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.